JM Goldman

9.7k total citations · 3 hit papers
83 papers, 7.4k citations indexed

About

JM Goldman is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, JM Goldman has authored 83 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 25 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in JM Goldman's work include Chronic Myeloid Leukemia Treatments (46 papers), Hematopoietic Stem Cell Transplantation (24 papers) and Acute Myeloid Leukemia Research (23 papers). JM Goldman is often cited by papers focused on Chronic Myeloid Leukemia Treatments (46 papers), Hematopoietic Stem Cell Transplantation (24 papers) and Acute Myeloid Leukemia Research (23 papers). JM Goldman collaborates with scholars based in United Kingdom, United States and Germany. JM Goldman's co-authors include Gale Rp, MM Horowitz, B Speck, HJ Kolb, Sondel Pm, Olle Ringdén, AA Rimm, JH Kersey, C Rozmán and William Arcese and has published in prestigious journals such as The Lancet, Blood and British Journal of Cancer.

In The Last Decade

JM Goldman

79 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Graft-versus-leukemia reactions after bone marrow transplantation

1990 2.1k citations MM Horowitz, Gale Rp et al. Blood profile →
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]

1995 1.5k citations HJ Kolb, JM Goldman et al. Blood profile →
T-cell depletion of HLA-identical transplants in leukemia

1991 581 citations MM Horowitz, Gale Rp et al. Blood profile →

Peers

Countries citing papers authored by JM Goldman

Since Specialization

Citations

This map shows the geographic impact of JM Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JM Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JM Goldman more than expected).

Fields of papers citing papers by JM Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JM Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JM Goldman. The network helps show where JM Goldman may publish in the future.

Co-authorship network of co-authors of JM Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of JM Goldman. A scholar is included among the top collaborators of JM Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JM Goldman. JM Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs 2002 ·Leukemia ·(unknown), F-X Mahon, (unknown), Valérie Lagarde, JM Goldman, JV Melo	67
2	Peripheral blood progenitor cell mobilisation alters myeloid, but not erythroid, progenitor cell self-renewal kinetics 2001 ·Bone Marrow Transplantation ·S. B. Marley, (unknown), Bo Zheng, (unknown), (unknown), Christine McDonald, (unknown), JM Goldman, M. Y. Gordon	4
3	Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia 2000 ·Bone Marrow Transplantation ·Pavlina Konstantinidou, Richard Szydlo, Andrew Chase, JM Goldman	7
4	Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM 2000 ·Leukemia ·(unknown), (unknown), JM Goldman, M. Y. Gordon	5
5	Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study 1999 ·Bone Marrow Transplantation ·(unknown), JM Goldman, Shaun R. McCann, A. C. Newland, J.H. Scarffe, (unknown), G J Mufti	129
6	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation 1998 ·The Lancet ·Aloïs Gratwohl, J. Hermans, JM Goldman, William Arcese, Enric Carreras, A Devergié, Francesco Frassoni, (unknown), HJ Kolb, D Niederwieser, Tapani Ruutu, Vernant Jp, T. de Witte, J. Apperley	451
7	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 1998 ·Bone Marrow Transplantation ·JM Goldman, Norbert Schmitz, D. Niethammer, Aloïs Gratwohl	77
8	Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia 1997 ·Leukemia ·Andrew Spencer, Tom Vulliamy, Jaspal Kaeda, JM Goldman, (unknown)	6
9	Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant 1997 ·Bone Marrow Transplantation ·Frederick Chen, (unknown), David G. Savage, S. A. Roberts, Jane F. Apperley, JM Goldman, Michael Laffan	73
10	BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients 1997 ·Leukemia ·(unknown), (unknown), Andrew Chase, Ian Titley, Lyn Healy, Andrew Spencer, Andreas Reiter, JM Goldman, M. Y. Gordon	13
11	Autografting for CML--overview and perspectives. 1996 ·PubMed ·JM Goldman	1
12	Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation 1996 ·Blood ·Jian‐Guo Zhang, Feng Lin, Andrew Chase, JM Goldman, Nicholas C.P. Cross	34
13	Quantitation of mafosfamide-resistant pre-colony-forming units in allogeneic bone marrow transplantation: relationship with rate of engraftment and evidence for long-lasting reduction in stem cell numbers 1996 ·Blood ·(unknown), Andrew Spencer, (unknown), Christine McDonald, JM Goldman	10
14	Advanced clinical monitoring: similar scenario discrimination. 1995 ·PubMed ·(unknown), JM Goldman	2
15	Myeloproliferative disorder associated with 8p11 translocations [letter; comment] 1995 ·Blood ·(unknown), D. Macdonald, (unknown), Nicholas C.P. Cross, JM Goldman	11
16	Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation 1993 ·Blood ·Nicholas C.P. Cross, Feng Lin, Andrew Chase, J Bungey, Terry P. Hughes, JM Goldman	314
17	Graft-versus-leukemia reactions after bone marrow transplantation breakdown → 1990 ·Blood ·MM Horowitz, Gale Rp, Sondel Pm, JM Goldman, JH Kersey, HJ Kolb, AA Rimm, Olle Ringdén, C Rozmán, B Speck	2116
18	Spinal cord compression in small cell lung cancer: a retrospective study of 610 patients 1989 ·British Journal of Cancer ·JM Goldman, (unknown), R L Souhami, DM Geddes, (unknown), SG Spiro, (unknown)	10
19	Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia 1988 ·Blood ·(unknown), Feyruz V. Rassool, (unknown), John Gow, (unknown), C Haworth, JM Goldman, (unknown)	15
20	Direct agonistic and antagonistic effects of ergotamine on vertebrate melanophores. 1970 ·PubMed ·JM Goldman, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact